» Articles » PMID: 16855502

Indications for Orbital Exenteration in Mucormycosis

Overview
Date 2006 Jul 21
PMID 16855502
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine whether evidence-based standards exist regarding the indications for orbital exenteration in patients with orbital mucormycosis.

Methods: A literature review was performed of 113 articles (1943 to 2004). Factors possibly related to patient survival were analyzed. Additionally, a survey was sent to all ASOPRS Fellowship Preceptors to ascertain the frequency, outcome, treatment modalities, and indications for exenteration by these practicing physicians.

Results: For published cases, parameter estimates (PE <or= 1.00) indicated that patients with mucormycosis with age >46 years, frontal sinus involvement, and fever were less likely to survive compared with patients without these conditions. Patients treated with amphotericin B (OR, 4.476) and those with diabetes (OR, 4.987) were more likely to survive compared with patients without these conditions. Exenterated patients with fever were more likely to survive compared with nonexenterated patients with fever (P=0.0468). Thirty-four ASOPRS Fellowship Preceptors received surveys; 26 (76%) completed the survey. Responses to specific survey questions showed a varied experience and indication for exenteration throughout the country.

Conclusions: : Our study underscores the lack of adequate data regarding the evaluation of treatment of orbital mucormycosis. No standard of care currently exists to guide physicians on when exenteration may benefit a mucormycosis patient. Further study is needed to determine which variables indicate the extent of disease and which variables or analytic scheme might predict the progression of orbital mucormycosis with or without exenteration.

Citing Articles

Estimation of the pattern of ocular manifestations, risk factors, and imaging of rhino-orbital-cerebral mucormycosis in COVID-19 patients.

Kaur R, Budhiraja G, Bhumbla U, Kaur M, Sharma V, Gupta P J Family Med Prim Care. 2025; 14(1):259-267.

PMID: 39989522 PMC: 11844987. DOI: 10.4103/jfmpc.jfmpc_1161_24.


Targeted orbital intervention in the management of sino-orbital mucormycosis cases.

Meel R, Bajaj M, Pushker N, Agrawal S, Tyagi P, Thakkar A Indian J Ophthalmol. 2024; 72(10):1488-1494.

PMID: 39331440 PMC: 11573022. DOI: 10.4103/IJO.IJO_18_24.


Resurgence of orbital mucormycosis during COVID-19 pandemic: Study from a tertiary care center in Eastern India.

Chakraborty S, Satty S, Sahu B, Ray S Taiwan J Ophthalmol. 2024; 14(2):256-261.

PMID: 39027069 PMC: 11253996. DOI: 10.4103/tjo.TJO-D-23-00110.


Prognostic factors and clinical features of rhino-orbital-mucormycosis cases: an update for patient and visual survivals.

Aksoy M, Ozcan A, Ulas B Int J Ophthalmol. 2024; 17(5):916-923.

PMID: 38766351 PMC: 11074210. DOI: 10.18240/ijo.2024.05.17.


Use of Temporalis Muscle and Temporoparietal Fasciocutaneous Flap (TPPF) for Orbital Exentration Defects: Our Experience of 10 Cases.

Sahni M, Patel P, Lakhera K, Singh S, Sharma R Indian J Otolaryngol Head Neck Surg. 2023; 75(4):3657-3662.

PMID: 37974706 PMC: 10645668. DOI: 10.1007/s12070-023-04054-z.